• A potent non-steroidal FXR agonist to treat NASH:
 - Mechanism of action that inhibits the synthesis of bile acid
 - Strong activity and selectivity demonstrated in nonclinical studies
 - Significantly reduced NAFLD Activity score and fibrosis in animal models of NASH
 - Regulated direct FXR target genes in a dose-dependent manner in vivo
 - Not importantly altered plasma level of ALT/AST and LDL-C at the effective dose
• IND submission expected in Q2 2022

NASH : NonAlcoholic SteatoHepatitis, NAFLD : NonAlcoholic Fatty Liver Disease,
FXR : Farnesoid X Receptor, ALT : Alanine aminotransferase,
AST : Aspartate aminotransferase, LDL-C : Low-Density Lipoprotein Cholesterol

• Migraine therapy with an innovative mechanism of action with no restrictions on use in cardiovascular disease patients
 - The first and only Ditan drug approved by the FDA with a different mechanism from triptans (serotonin 1B receptor agonists) and NSAIDs, which have been used as migraine treatments.
 - Overcoming the limitations of existing triptans (limited use in cardiovascular patients) by exhibiting 470-fold or more affinity for serotonin 1F receptors compared to serotonin 1B and 1D receptors associated with vasoconstriction
• NDA submitted in Korea in Q1 2021

NSAIDs : Non-steroidal anti-inflammatory drugs

• A GPR40 agonist to treat type 2 diabetes mellitus
 - High oral absolute bioavailability in pre-clinical species
 - A defined MoA, activating β-arrestin2 recruitment as well as Gq-dependent pathway
 - Glucose-dependent insulin secretion & free of hypoglycemic risk
 - Superior to fasiglifam in glucose reduction in normal and diabetic rat studies
 - Potentially no risk of DILI (drug-induced liver injury)
• Phase 1 has started in Germany in July 2021 to evaluate safety and pharmacokinetics (NCT04982705)

•A small-molecule glucagon-like peptide (GLP)-1 receptor agonist to treat type 2 diabetes
 - Being developed as an oral drug
 - Overcame the disadvantages of existing injection drugs (improved safety profile and
    patient adherence)
 - Potential of expansion to various indications including NASH and Obesity
• IND submission expected in Q1 2023

GLP-1 : Glucagon-like peptide-1, NASH : NonAlcoholic SteatoHepatitis

• A dual-targeting antibody fragment drug for wet AMD
 - A VEGF-A/NRP1 dual-targeting antibody fragment engineered through tissue-penetrating
    peptide technology
 - Enhanced efficacy by inhibiting multiple pro-angiogenic growth factors
 - Targets bi- to tri-monthly dosing interval based on improved ocular PK 
 - Possibility of non-invasive drug administration through tissue-penetrating peptides
• No known systemic safety issues by GLP tox study​
• Pre-clinical development accelerated through Lonza’s CMC platform
• Accelerating CMC development with Global CDMO

• First-in-class small molecule CFTR activator to treat dry eye disease
 - has a novel mode of action to increase tear secretion
 - targets to improve both signs and symptoms with favorable tolerability profile and simplified dosing
• IND submission expected in Q4 2022

CFTR : Cystic Fibrosis Transmembrane Regulator

• A nitric oxide-donating PDE5 inhibitor for Glaucoma
 - Metabolized in the body to release nitric oxide and at the same time inhibits PDE5/6 to
     increase PKG (protein kinase G) activity
 - Activates PKG by increasing the amount of cGMP by inhibiting the degradation of cGMP
 - Activated PKG relaxes smooth muscle and increases blood flow

cGMP : Cyclic Guanosine MonoPhosphate

• A nitric oxide-donating PDE5 inhibitor for ARDS, PAH
 - Highly selective and potent in vitro activity
 - Efficacy shown in an acute lung injury mouse model
• in vivo efficacy study, formulation, PK analysis are on-going
• IND submission expected in 1Q 2023

ARDS : Acute Respiratory Distress Syndrome, PDE5 : PhosphoDiEsterase 5